Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 7712 results

  1. Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer

    Awaiting development [GID-IPG10412] Expected publication date: 13 November 2025

    Interventional procedures guidance
    Awaiting development

  2. Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults

    In development [GID-IPG10411] Expected publication date: 06 August 2025

    Interventional procedures guidance
    In development

  3. Balloon cryoablation for Barrett's oesophagus

    Awaiting development [GID-IPG10413] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  4. Linaclotide acetate for treating Chronic idiopathic constipation [TS ID 12005]

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Baloxavir marboxil for Influenza

    Awaiting development [GID-TA11646] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Topical antimicrobial dressings for infected leg ulcers in people aged 16 and over: Late stage assessment

    In development [GID-HTE10041] Expected publication date: 22 May 2025

    Health technology evaluations
    In development

  8. Iptacopan for treating complement 3 glomerulopathy ID6283

    In development [GID-TA11331] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development [GID-TA11087] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232

    Awaiting development [GID-TA11230] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]

    Awaiting development [GID-TA11231] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Awaiting development [GID-TA11018] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (DG59)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    Diagnostics guidance
    Published
    31 July 2024
    View recommendations

    Sections for DG59